{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T05:05:42Z","timestamp":1771218342203,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,15]]},"DOI":"10.7759\/cureus.103676","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T04:23:15Z","timestamp":1771215795000},"source":"Crossref","is-referenced-by-count":0,"title":["A Randomized, Multicenter Study Evaluating the Efficacy, Safety and Tolerability of Dapagliflozin + Gliclazide Fixed Dose Combination Over Dapagliflozin Monotherapy in Type 2 Diabetes Mellitus Patients Inadequately Controlled on Metformin Monotherapy"],"prefix":"10.7759","author":[{"given":"Suhas G","family":"Erande","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amar","family":"Raykantiwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Shejole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi","family":"GR","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Animesh","family":"Maiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.S. Veeramani","family":"Kartheek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Hanifah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richa","family":"Giri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharvil","family":"Gadve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arindam","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunal","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balram","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saket","family":"Kant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhyudaya","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogesh","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiren","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honey","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S001","article-title":"Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2026","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes*","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes*. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2026. Diabetes Care. 2026, 49:S13-26. 10.2337\/dc26-S001","journal-title":"Diabetes Care"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf177","article-title":"IDF Diabetes Atlas 11th edition 2025: global prevalence and projections for 2050","volume":"41","author":"Duncan BB","year":"2025","unstructured":"Duncan BB, Magliano DJ, Boyko EJ. IDF Diabetes Atlas 11th edition 2025: global prevalence and projections for 2050. Nephrol Dial Transplant. 2025, 41:7-9. 10.1093\/ndt\/gfaf177","journal-title":"Nephrol Dial Transplant"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02317-1","article-title":"Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants","volume":"404","author":"NCD Risk Factor Collaboration","year":"2024","unstructured":"NCD Risk Factor Collaboration. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet. 2024, 404:2077-93. 10.1016\/S0140-6736(24)02317-1","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000654","article-title":"Real-world evidence of glycemic control among patients with type 2 diabetes mellitus in India: the TIGHT study","volume":"7","author":"Borgharkar SS","year":"2019","unstructured":"Borgharkar SS, Das SS. Real-world evidence of glycemic control among patients with type 2 diabetes mellitus in India: the TIGHT study. BMJ Open Diabetes Res Care. 2019, 7:e000654. 10.1136\/bmjdrc-2019-000654","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies MJ","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al.. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022, 45:2753-86. 10.2337\/dci22-0034","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update","volume":"29","author":"Samson SL","year":"2023","unstructured":"Samson SL, Vellanki P, Blonde L, et al.. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update. Endocr Pract. 2023, 29:305-40. 10.1016\/j.eprac.2023.02.001","journal-title":"Endocr Pract"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2023.1816","article-title":"Initial combination therapy in type 2 diabetes","volume":"39","author":"Kim JY","year":"2024","unstructured":"Kim JY, Kim NH. Initial combination therapy in type 2 diabetes. Endocrinol Metab (Seoul). 2024, 39:23-32. 10.3803\/EnM.2023.1816","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.70780","article-title":"Patient adherence for oral combination therapies in diabetes management: a scoping review","volume":"8","author":"Zarrinkamar M","year":"2025","unstructured":"Zarrinkamar M, Geran M, Geran M. Patient adherence for oral combination therapies in diabetes management: a scoping review. Health Sci Rep. 2025, 8:e70780. 10.1002\/hsr2.70780","journal-title":"Health Sci Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0666","article-title":"Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial","volume":"38","author":"Matthaei S","year":"2015","unstructured":"Matthaei S, Bowering K, Rohwedder K, et al.. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diab Car. 2015, 38:365-72. 10.2337\/dc14-0666","journal-title":"Diab Car"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01314.x","article-title":"Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects","volume":"13","author":"Kasichayanula S","year":"2011","unstructured":"Kasichayanula S, Liu X, Shyu WC, et al.. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab. 2011, 13:47-54. 10.1111\/j.1463-1326.2010.01314.x","journal-title":"Diabetes Obes Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_225_20","article-title":"RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020","volume":"24","author":"Chawla R","year":"2020","unstructured":"Chawla R, Madhu SV, Makkar BM, et al.. RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. Indian J Endocrinol Metab. 2020, 24:1-122. 10.4103\/ijem.IJEM_225_20","journal-title":"Indian J Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01458-6","article-title":"The role of real-world evidence in treatment decision-making, regulatory assessment, and understanding the perspectives of people with type\u00a02 diabetes: examples with gliclazide MR","volume":"14","author":"Khunti K","year":"2023","unstructured":"Khunti K, Almalki M, Chan JC, Amod A. The role of real-world evidence in treatment decision-making, regulatory assessment, and understanding the perspectives of people with type\u00a02 diabetes: examples with gliclazide MR. Diabetes Ther. 2023, 14:1609-25. 10.1007\/s13300-023-01458-6","journal-title":"Diabetes Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03394-2","article-title":"ADD2Dia: real-world clinical effectiveness of adding a sodium-glucose cotransporter\u00a02 inhibitor to gliclazide-based therapy in type\u00a02 diabetes","volume":"42","author":"Moreira RO","year":"2025","unstructured":"Moreira RO, Nicodemus NA Jr, Comlekci A, et al.. ADD2Dia: real-world clinical effectiveness of adding a sodium-glucose cotransporter\u00a02 inhibitor to gliclazide-based therapy in type\u00a02 diabetes. Adv Ther. 2025, 42:6295-309. 10.1007\/s12325-025-03394-2","journal-title":"Adv Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2491","article-title":"Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial","volume":"36","author":"Schernthaner G","year":"2013","unstructured":"Schernthaner G, Gross JL, Rosenstock J, et al.. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013, 36:2508-15. 10.2337\/dc12-2491","journal-title":"Diabetes Care"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16218","article-title":"Fixed dose combination of dapagliflozin, glimepiride and extended-release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase III, open label, randomized clinical study in India","volume":"27","author":"Sahay R","year":"2025","unstructured":"Sahay R, Gangwani D, Singh M, et al.. Fixed dose combination of dapagliflozin, glimepiride and extended-release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase III, open label, randomized clinical study in India. Diabetes Obes Metab. 2025, 27:2193-205. 10.1111\/dom.16218","journal-title":"Diabetes Obes Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01612-8","article-title":"Current position of gliclazide and sulfonylureas in the contemporary treatment paradigm for type 2 diabetes: a scoping review","volume":"15","author":"Sahin I","year":"2024","unstructured":"Sahin I, Bakiner O, Demir T, et al.. Current position of gliclazide and sulfonylureas in the contemporary treatment paradigm for type 2 diabetes: a scoping review. Diabetes Ther. 2024, 15:1687-716. 10.1007\/s13300-024-01612-8","journal-title":"Diabetes Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/451173-a-randomized-multicenter-study-evaluating-the-efficacy-safety-and-tolerability-of-dapagliflozin--gliclazide-fixed-dose-combination-over-dapagliflozin-monotherapy-in-type-2-diabetes-mellitus-patients-inadequately-controlled-on-metformin-monotherapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T04:23:16Z","timestamp":1771215796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/451173-a-randomized-multicenter-study-evaluating-the-efficacy-safety-and-tolerability-of-dapagliflozin--gliclazide-fixed-dose-combination-over-dapagliflozin-monotherapy-in-type-2-diabetes-mellitus-patients-inadequately-controlled-on-metformin-monotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.103676","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,15]]}}}